Arrowhead plans sNDA by end of 2026 as SHASTA shows 79%-81% triglyceride reductions and 78% fewer pancreatitis events
This is a summary aggregated from Seeking Alpha. Read the complete article on the original site:
Read full article at Seeking Alpha
